Literature DB >> 19204689

The cancer vaccine roller coaster.

Bruce Goldman, Laura DeFrancesco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19204689     DOI： 10.1038/nbt0209-129

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  7 in total

1.  Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

Authors:  E J Small; P Fratesi; D M Reese; G Strang; R Laus; M V Peshwa; F H Valone
Journal:  J Clin Oncol       Date:  2000-12-01       Impact factor: 44.544

Review 2.  Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention.

Authors:  Theresa L Whiteside
Journal:  Semin Cancer Biol       Date:  2005-09-08       Impact factor: 15.707

3.  An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.

Authors:  Christopher Wood; Pramod Srivastava; Ronald Bukowski; Louis Lacombe; Andrei I Gorelov; Sergei Gorelov; Peter Mulders; Henryk Zielinski; Axel Hoos; Florentina Teofilovici; Leah Isakov; Robert Flanigan; Robert Figlin; Renu Gupta; Bernard Escudier
Journal:  Lancet       Date:  2008-07-03       Impact factor: 79.321

4.  Trouble at the office.

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2008-09       Impact factor: 54.908

5.  Dendritic cell-based treatment of cancer: closing in on a cellular therapy.

Authors:  F H Valone; E Small; M MacKenzie; P Burch; M Lacy; M V Peshwa; R Laus
Journal:  Cancer J       Date:  2001 Nov-Dec       Impact factor: 3.360

Review 6.  Clinical results of vaccine therapy for cancer: learning from history for improving the future.

Authors:  Aniruddha Choudhury; Szilvia Mosolits; Parviz Kokhaei; Lotta Hansson; Marzia Palma; Håkan Mellstedt
Journal:  Adv Cancer Res       Date:  2006       Impact factor: 6.242

7.  Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

Authors:  Alessandro Testori; Jon Richards; Eric Whitman; G Bruce Mann; Jose Lutzky; Luis Camacho; Giorgio Parmiani; Giulio Tosti; John M Kirkwood; Axel Hoos; Lianng Yuh; Renu Gupta; Pramod K Srivastava
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544
  7 in total
  64 in total

1.  A methodological framework to enhance the clinical success of cancer immunotherapy.

Authors:  Axel Hoos; Cedrik M Britten; Christoph Huber; Jill O'Donnell-Tormey
Journal:  Nat Biotechnol       Date:  2011-10-13       Impact factor: 54.908

2.  An empiric victory.

Authors: 
Journal:  Nat Biotechnol       Date:  2010-06       Impact factor: 54.908

3.  Landmark approval for Dendreon's cancer vaccine.

Authors:  Laura DeFrancesco
Journal:  Nat Biotechnol       Date:  2010-06       Impact factor: 54.908

Review 4.  Lung cancer vaccines.

Authors:  Ronan J Kelly; Giuseppe Giaccone
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 5.  The role of glycans in immune evasion: the human fetoembryonic defence system hypothesis revisited.

Authors:  Gary F Clark
Journal:  Mol Hum Reprod       Date:  2013-09-15       Impact factor: 4.025

6.  CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice.

Authors:  Li-Xin Wang; Yuhuan Li; Guojun Yang; Pui-yi Pang; Dan Haley; Edwin B Walker; Walter J Urba; Hong-Ming Hu
Journal:  Eur J Immunol       Date:  2010-05       Impact factor: 5.532

Review 7.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

Review 8.  Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.

Authors:  Samaresh Sau; Hashem O Alsaab; Ketki Bhise; Rami Alzhrani; Ghazal Nabil; Arun K Iyer
Journal:  J Control Release       Date:  2018-01-31       Impact factor: 9.776

9.  Translational medicine--doing it backwards.

Authors:  Robert B Nussenblatt; Francesco M Marincola; Alan N Schechter
Journal:  J Transl Med       Date:  2010-02-08       Impact factor: 5.531

Review 10.  Strategies for cancer vaccine development.

Authors:  Matteo Vergati; Chiara Intrivici; Ngar-Yee Huen; Jeffrey Schlom; Kwong Y Tsang
Journal:  J Biomed Biotechnol       Date:  2010-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.